NASDAQ:GILD
62.98
0.22
(0.35%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia
Analysis and Opinions about GILD-Q
Signal
Opinion
Expert
DON'T BUY
DON'T BUY
January 17, 2020
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
Show full opinionHide full opinion
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
HOLD
HOLD
August 27, 2019
A drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
Show full opinionHide full opinionA drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
DON'T BUY
DON'T BUY
August 22, 2019
It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.
It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.
BUY
BUY
July 17, 2019
It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
Show full opinionHide full opinionIt's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
PAST TOP PICK
PAST TOP PICK
May 29, 2019
(A Top Pick Jun 27/18, Down 5%) An analyst just issued a sell report on them -- calling for a 10% downturn. It trades about 8.5 times earnings. They were victims of their success in hepatitis medicine as it cured too many people, he says. It pays a 4% yield.
Show full opinionHide full opinion(A Top Pick Jun 27/18, Down 5%) An analyst just issued a sell report on them -- calling for a 10% downturn. It trades about 8.5 times earnings. They were victims of their success in hepatitis medicine as it cured too many people, he says. It pays a 4% yield.
BUY
BUY
May 3, 2019
Value trap for so long for so many. Cure for Hep C had generated huge cash flow. HIV franchise is leading the pack. Yesterday's numbers are fantastic. Likes that they've diversified their assets. New CEO gave realistic guidance. Likes it at these levels.
Show full opinionHide full opinionValue trap for so long for so many. Cure for Hep C had generated huge cash flow. HIV franchise is leading the pack. Yesterday's numbers are fantastic. Likes that they've diversified their assets. New CEO gave realistic guidance. Likes it at these levels.
N/A
N/A
March 14, 2019
The pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
Show full opinionHide full opinionThe pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
HOLD
HOLD
March 13, 2019
He's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
Show full opinionHide full opinionHe's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
DON'T BUY
DON'T BUY
March 6, 2019
Stay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
Show full opinionHide full opinionStay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
HOLD
HOLD
December 21, 2018
He still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
Show full opinionHide full opinionHe still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
WATCH
WATCH
December 3, 2018
A frustrating stock. They have expensive drugs, such as for hepatitis C. They failed to build out their franchise and not making acquisitions, and have only been doing that in the past few years. Their HIV franchise is doing quite well, though. They acquired Kite Pharma which could be a game-changer later. It's trading at 10x earnings. Upcoming catalysts are a liver study in Q1/Q2 could be positive. Maybe. But is GILD a value trap or opportunity? Buy it as its chart improves.
Show full opinionHide full opinionA frustrating stock. They have expensive drugs, such as for hepatitis C. They failed to build out their franchise and not making acquisitions, and have only been doing that in the past few years. Their HIV franchise is doing quite well, though. They acquired Kite Pharma which could be a game-changer later. It's trading at 10x earnings. Upcoming catalysts are a liver study in Q1/Q2 could be positive. Maybe. But is GILD a value trap or opportunity? Buy it as its chart improves.
TOP PICK
TOP PICK
November 29, 2018
Value play. It's been hammered, trading at around 10X future PE, cheap. The market is valuing their HCV business to basically zero, and that's the side of the business that's been hurt with the generics coming out and pushing the prices lower. Their HIV business has been doing pretty well. New CEO coming in, they have $32B in cash and waiting to see how this cash will be spent. Yield 3.3%. (Analysts’ price target is $86.95)
Show full opinionHide full opinionValue play. It's been hammered, trading at around 10X future PE, cheap. The market is valuing their HCV business to basically zero, and that's the side of the business that's been hurt with the generics coming out and pushing the prices lower. Their HIV business has been doing pretty well. New CEO coming in, they have $32B in cash and waiting to see how this cash will be spent. Yield 3.3%. (Analysts’ price target is $86.95)
WAIT
WAIT
November 26, 2018
Has had a pullback over the last 3 years. Their return on capital has gone down. They have had tough competition and some products going off patent. He would wait to see improved results before he decided on a position.
Show full opinionHide full opinionHas had a pullback over the last 3 years. Their return on capital has gone down. They have had tough competition and some products going off patent. He would wait to see improved results before he decided on a position.
DON'T BUY
DON'T BUY
November 21, 2018
This is a US biotechnology company. They are big on treatments for HIV and hepatitis. It trades at a cheap valuation. There is competition from other big pharma and generics and biologics. It is reasonably cheap but depends on finding new markets for their drugs.
Show full opinionHide full opinionThis is a US biotechnology company. They are big on treatments for HIV and hepatitis. It trades at a cheap valuation. There is competition from other big pharma and generics and biologics. It is reasonably cheap but depends on finding new markets for their drugs.
BUY
BUY
October 29, 2018
Has long owned it and likes it. They had some bad years when they overpriced their hepatitis C drug and received bad press. They also sell HIV and heart drugs, sectors that are growing. They increased their guidance last week, a rarity these days. At 10x earnings, he'd buy it, not sell it. One overhang is that their CEO is leaving.
Has long owned it and likes it. They had some bad years when they overpriced their hepatitis C drug and received bad press. They also sell HIV and heart drugs, sectors that are growing. They increased their guidance last week, a rarity these days. At 10x earnings, he'd buy it, not sell it. One overhang is that their CEO is leaving.
